Action HCWB HCW BIOLOGICS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues HCW Biologics Inc.

Actions

HCWB

US40423R1059

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
0,647 USD +1,08 % Graphique intraday de HCW Biologics Inc. -10,50 % -47,18 %
15/05 HCW Biologics Inc. déclare ses résultats pour le premier trimestre clos le 31 mars 2024 CI
01/04 HCW Biologics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
HCW Biologics Inc. announced that it expects to receive $10 million in funding
HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
HCW Biologics Inc. Enters into A Senior Secured Note Purchase Agreement with Purchasers
HCW Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
HCW Biologics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
HCW Biologics Inc. announced that it has received $2.500005 million in funding
HCW Biologics Inc. Exercises Its Right to Terminate Its Credit Agreement
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q3 Revenue $853,102
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
HCW Biologics Inc. Announces Results from Preliminary Human Data Readout from an Ongoing Phase 1 Clinical Trial Sponsored by the University of Minnesota
HCW Biologics : First-in-Human Clinical Readout of HCW9218, SITC 2023
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
HCW Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Earnings Flash (HCWB) HCW BIOLOGICS Reports Q2 Revenue $622,807
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HCWB
  4. Actualités HCW Biologics Inc.
  5. Autres langues